Healthy volunteers compare two cabergoline versions in bioequivalence trial
NCT ID NCT07008417
First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study checks whether a new cabergoline tablet works the same as the standard version in 72 healthy Chinese adults aged 18-45. Participants take one dose under fasting and one after a meal, with blood tests to compare drug levels. The goal is to confirm the tablets are equivalent, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPROLACTINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, 200233, China
Conditions
Explore the condition pages connected to this study.